Efficacy and Safety of Donepezil Hydrochloride in Preadolescent and Adolescent Children With Attention Impairment Following Cancer Treatment

December 14, 2021 updated by: Eisai Inc.

Randomized, Double-Blind, Placebo-Controlled Study of Efficacy and Safety of Donepezil Hydrochloride in Preadolescent and Adolescent Children With Attention Impairment Following Cancer Treatment

The purpose of this study is to evaluate the efficacy, safety and tolerability of donepezil in children with persistent attention impairment that is present at least 12 months after the completion of cancer treatment.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

This is a double-blind, placebo-controlled, parallel group study in pediatric subjects who have persistent attention impairment following treatment for cancer. This trial has three phases: (1) pre-randomization to establish eligibility, (2) a 12-week, double-blind, placebo-controlled, parallel-group phase with dose escalation based on body weight, (3) a 12-week, blinded extension phase during which all subjects will receive active drug.

Study Type

Interventional

Enrollment (Actual)

72

Phase

  • Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Argentina
      • Buenos Aires, Argentina, C1181ACH
      • Buenos Aires, Argentina, C1428AQK
    • Provincia De Cordoba
      • Cordoba Capital, Provincia De Cordoba, Argentina, 5000
  • Australia
    • New South Wales
      • Sydney, New South Wales, Australia, 2301
      • Westmead, Sydney, New South Wales, Australia, 2045
  • Canada
    • Alberta
      • Calgary, Alberta, Canada, T2T5C7
  • Chile
    • Providencia Santiago
      • Antonio Varas, Providencia Santiago, Chile, 360
      • Santa Maria, Providencia Santiago, Chile, 0410
  • France
      • Vandoeurvre Les Nancy, France, 54511
      • Villejuif, France, 94805
  • Germany
      • Koeln, Germany, 50924
  • Netherlands
      • Amsterdam, Netherlands, 1081 HV
      • Groningen, Netherlands, 9713 GZ
      • Rotterdam, Netherlands, 3015 GJ
      • Utrecht, Netherlands, 3584 EA
  • Spain
      • Palma de Mallorca, Spain, 07198
      • Valencia, Spain, 46009
  • United Kingdom
    • Surrey
      • Sutton, Surrey, United Kingdom, SM2 5PT
  • United States
    • California
      • Stanford, California, United States, 94305-5826
    • Florida
      • Miami, Florida, United States, 33155
    • Minnesota
      • Minneapolis, Minnesota, United States, 55404
    • Missouri
      • Saint Louis, Missouri, United States, 63110
    • New Jersey
      • New Brunswick, New Jersey, United States, 08903
    • New York
      • Brooklyn, New York, United States, 11209
      • Great Neck, New York, United States, 10021
      • New York, New York, United States, 10065
    • North Carolina
      • Chapel Hill, North Carolina, United States, 27514
    • Oklahoma
      • Oklahoma City, Oklahoma, United States, 73104
    • Texas
      • Dallas, Texas, United States, 75235
      • Houston, Texas, United States, 77030
      • San Antonio, Texas, United States, 78258
        • Road Runner Research Ltd.

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

6 years to 17 years (Child)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

  1. The subject must have received at least one cycle of chemotherapy and/or cranial radiation, and must have completed this treatment at least one year before screening takes place for entry into this study.
  2. Subjects may be male or female; age range: 6 - 17.5 years; weight ≥ 20 kg. They must be physically healthy and able to move about, with or without aids, must be living in the community, and must have adequate motor skills as shown by tests that will be given at the time of screening. The subject's eyesight and hearing must be good enough to allow cooperation with tests and physical examinations. Additionally, they must be able to swallow tablets.
  3. There must be subjective complaints by subject and/or parent of difficulties in school or other daily activities, possibly related to impairments in attention. These difficulties must have emerged after treatment for cancer and must still be present 12 months after cessation of treatment. There must also be objective evidence for this impairment, as shown by a test that will be given to the subject at the time of screening.
  4. The IQ must be >70 according to tests that will be given at the time of screening.
  5. The first language in which the subject learned to read and write must be one that uses Roman lettering (a, b, c, etc.) and Arabic numerals (1, 2, 3, etc.).
  6. The subject must not have previously taken any drugs in the class known as cholinesterase inhibitors.
  7. A parent or legal guardian must be available who is willing and able to complete all of the outcome measures, to administer medications, and to accompany the subject to the required clinic visits.
  8. Subjects with diabetes or thyroid disease may still be eligible if certain medical requirements are satisfied.
  9. Female subjects who could become pregnant must undergo pregnancy testing and must agree to use contraception.

Exclusion Criteria:

Subjects who meet any of the following criteria will be excluded from the study:

  1. Inability to perform the required tests (for example, because of aphasia, motor deficits affecting the dominant hand, or mental retardation).
  2. Motor coordination not sufficient, according to tests to be conducted at the time of screening.
  3. Recurrence of cancer. If this happens, the subject will have to withdraw from the study.
  4. Mental retardation/developmental disability.
  5. Certain medications, such as methylphenidate, are not allowed during the study.
  6. Major depression.
  7. Problems with the digestive tract that could affect the subject's ability to absorb the study drug.
  8. Hypersensitivity to a chemical class known as piperidine derivatives.
  9. Certain other medical conditions as determined by clinical staff.
  10. Alcoholism, drug abuse, or organic brain disease other than that caused by the cancer or its treatment.
  11. Pregnancy, nursing, or unwillingness to undergo pregnancy testing if requested by clinical staff.
  12. Pregnancy, lactation or plans to become pregnant, or unwilling to take a screening Beta-human chorionic gonadotropin (ßhCG) test if a female >10 years of age.
  13. If sexually active, unwillingness to use birth control (males and females).
  14. Plans for certain types of elective surgery that would occur while the study is in progress.
  15. Plans for travel or other events that would interfere with the study schedule.
  16. Active treatment with another investigational drug within 3 months of the screening visit.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: 1
Drug: Donepezil hydrochloride

During the 12-week Double-Blind Phase, subjects will receive oral donepezil hydrochloride tablets starting at a dose of 3 mg once daily. Doses will be increased incrementally at successive 3-week intervals on the basis of weight and tolerability. The final daily dose will be 3, 5, or 10 mg depending on body weight.

During the Blinded Extension Phase, all subjects will receive active treatment (donepezil).

Other Names:
  • Aricept
Placebo Comparator: 2
Drug: Placebo

During the 12-week Double-Blind Phase, subjects will receive matching placebo tablets (3, 5, of 10 mg) once daily.

During the 12-week Blinded Extension Phase, all subjects will receive active treatment (donepezil).

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change From Baseline in the Test of Variables in Attention-Continuous Performance Test (TOVA-CPT) "D-prime" Standard Score (SS) at Week 12
Time Frame: Baseline and Week 12
TOVA-CPT test has a standardized computer game-like format that tests attention and simple impulse control. It precisely measures a person's reaction time to clicking on correct targets versus incorrect targets. Scores are based on the number of "Hits" (correct responses), omission errors (failure to respond), commission errors/"False Alarms" (incorrect responses), response time, and sensitivity ("d-prime"). "D-prime" a dimensionless statistics is a measure of distractibility and reflects how well a person reacts correctly versus incorrectly. A higher value of "d-prime" is reached by having more "Hits" (correct response) and fewer "False Alarms" (incorrect response). Analysis was based on three factors: the "d-prime" standard score, reaction time variability standard score, and response time standard score. Standard scores less than or equal to 80 were significant for an attention deficit disorder. Standard scores greater than 80 were not significant for an attention deficit disorder.
Baseline and Week 12

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change From Baseline in the TOVA-CPT "D-prime" Standard Score (SS) at Week 6
Time Frame: Baseline and Week 6
TOVA-CPT test has a standardized computer game-like format that tests attention and simple impulse control. It precisely measures a person's reaction time to clicking on correct targets versus incorrect targets. Scores are based on the number of "Hits" (correct responses), omission errors (failure to respond), commission errors/"False Alarms" (incorrect responses), response time, and sensitivity ("d-prime"). "D-prime" a dimensionless statistics is a measure of distractibility and reflects how well a person reacts correctly versus incorrectly. A higher value of "d-prime" is reached by having more "Hits" (correct response) and fewer "False Alarms" (incorrect response). Analysis was based on three factors: the "d-prime" standard score, reaction time variability standard score, and response time standard score. Standard scores less than or equal to 80 were significant for an attention deficit disorder. Standard scores greater than 80 were not significant for an attention deficit disorder.
Baseline and Week 6
Change From Baseline in the Reaction Time Variability Standard Score (RTVSS) and Response Time Standard Score (RTSS) at Weeks 6 and 12
Time Frame: Baseline, Weeks 6 and 12
The Reaction Time Variability is defined as the time measurement of how consistently the switch is pressed. The Response Time is the measurement of how fast or slow information is processed and responded to by the participant. The testing process was as described in a previous outcome measure. Standard scores less than or equal to 80 were significant for an attention deficit disorder. Standard scores greater than 80 were not significant for an attention deficit disorder.
Baseline, Weeks 6 and 12
Change From Baseline in the Global Executive Composite Score, Behavioral Regulation Index, Metacognition Index, and Working Memory Subscale
Time Frame: Baseline and Week 12
Behavioral Rating Inventory of Executive Functioning test evaluates impairment of executive function(planning and organization),memory,and sustained attention in children aged 5-18 years with wide range of developmental and acquired neurological conditions.Survey assess parent/guardian's perception of their child's executive functioning in home and school environments,which relate to daily function(as judged by parent).Each survey contains 86 items scored as;1(behavior is never a problem),2(behavior is sometimes a problem),or 3(behavior is often a problem).Data was presented as t-scores(raw scale scores are used to generate t-scores)for Global Executive Composite Score(t-score range 72-216),Behavioral Regulation Index(t-score range 28-84;inhibit,shift,and emotional control),Metacognition Inde (t-score range 44-132;initiate,working memory,plan/organize,organization of materials, and monitor),and Working Memory Subscale(t-score range 35-90).Higher scores indicate decline in performance.
Baseline and Week 12

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Eisai Inc.

Collaborators

Eisai Limited

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

July 2, 2008

Primary Completion (Actual)

May 26, 2009

Study Completion (Actual)

May 26, 2009

Study Registration Dates

First Submitted

May 28, 2008

First Submitted That Met QC Criteria

May 30, 2008

First Posted (Estimate)

June 2, 2008

Study Record Updates

Last Update Posted (Actual)

January 5, 2022

Last Update Submitted That Met QC Criteria

December 14, 2021

Last Verified

November 1, 2015

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • E2020-G000-333
  • E2020-G000-334 (Registry Identifier: NCT00687635)
  • 2007-005435-28 (EudraCT Number)

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Attention Impairment

Clinical Trials on Donepezil hydrochloride

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Cameroon

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe